Evidence map›Paper›PMID 40037156›Full record

ReviewThe Journal of surgical research2025

Contemporary Management of Malignant Ascites.

Mason A Vierra, Ryan B Morgan, Neal Bhutiani, Michael G White, Oliver S Eng

Abstract readReview
In one paragraph

Review in The Journal of surgical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mason A VierraDepartment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: mvierra@mgb.org.
Ryan B MorganDepartment of Surgery, University of Chicago Medical Center, Chicago, Illinois.
Neal BhutianiDepartment of Surgery, University of Louisville, Louisville, Kentucky.
Michael G WhiteDepartment of Colon & Rectal Surgery, MD Anderson Cancer Center, Houston, Texas.
Oliver S EngDepartment of Surgery, University of California Irvine, Orange, California.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
CTSA K12 Program at The University of Texas Health Science Center at HoustonK12TR004908 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Charles C Miller, JON E. TYSON · 2024 to 2026
$2.9M
NCATS NIH HHS K12 TR004908NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

introductionMalignant ascites (MA) develops when malignant disease of the peritoneum causes excess fluid to accumulate in the abdominal cavity. It portends a poor prognosis and is associated with debilitating symptoms. While several palliative therapies exist, none have proven curative or free from side effects and complications. This review article describes experimental therapies on the horizon and the contemporary management of MA. MATERIALS AND

methodsA literature review was performed using MEDLINE/PubMed, in which studies of emerging or experimental therapies under investigation for the management of MA were reviewed. Current therapies were also reviewed to provide important context. Data, including study design, sample size, primary and secondary outcomes, and side effects were recorded and described. Studies were then categorized into distinct sections and subsections, with tables corresponding to each section.

resultsFive current therapies, including paracentesis, diuretics, peritoneovenous shunting, permanent catheters, and intraperitoneal chemotherapy, are described. Their limitations in effectively managing MA are highlighted. The "Experimental therapies" section is subsectioned into several categories, with the major studies corresponding to each section thoroughly described regarding methods, results, and validity. A final section describes treatments for mucinous ascites, which has distinct characteristics.

conclusionsWhile each of the experimental therapies described offers unique benefits and has demonstrated some promise in managing MA, they all have limitations that have thus far prevented any one of them from being routinely used in practice. MA remains a challenging condition to treat, warranting further research into novel therapies.

Indexed as

AscitesPeritoneal NeoplasmsAntineoplastic AgentsDiureticsHumansPalliative CareParacentesisPeritoneovenous ShuntAntineoplastic AgentsDiureticsCatumaxomabMalignant ascitesMucinous ascitesParacentesisPeritoneal carcinomatosis

Identifiers

PMID40037156
PMCPMC12244293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.